TY - JOUR
T1 - New antibacterial agents
T2 - Hybrid bioisoster derivatives as potential E. coli FabH inhibitors
AU - Segretti, Natanael D.
AU - Serafim, Ricardo A. M.
AU - Segretti, Mariana C. F.
AU - Miyata, Marcelo
AU - Coelho, Fernando R.
AU - Augusto, Ohara
AU - Ferreira, Elizabeth I.
PY - 2016/8/15
Y1 - 2016/8/15
N2 - The development of resistance to antibiotics by microorganisms is a major problem for the treatment of bacterial infections worldwide, and therefore, it is imperative to study new scaffolds that are potentially useful in the development of new antibiotics. In this regard, we propose the design, synthesis and biological evaluation of hybrid sulfonylhydrazone bioisosters/furoxans with potential antibacterial (Escherichia coli) activity. The most active compound of the series, (E)-3-methyl-4-((2-tosylhydrazono)methyl)-1,2,5-oxadiazole 2-oxide, with a MIC = 0.36 mu M, was not cytotoxic when tested on Vero cells (IC50 > 100 mu M). To complement the in vitro screening, we also studied the interaction of the test compounds with beta-ketoacyl acyl carrier protein synthase (FabH), the target for the parent compounds, and we observed three important hydrogen-bonding interactions with two important active site residues in the catalytic site of the enzyme, providing complementary evidence to support the target of the new hybrid molecules. (C) 2016 Elsevier Ltd. All rights reserved.
AB - The development of resistance to antibiotics by microorganisms is a major problem for the treatment of bacterial infections worldwide, and therefore, it is imperative to study new scaffolds that are potentially useful in the development of new antibiotics. In this regard, we propose the design, synthesis and biological evaluation of hybrid sulfonylhydrazone bioisosters/furoxans with potential antibacterial (Escherichia coli) activity. The most active compound of the series, (E)-3-methyl-4-((2-tosylhydrazono)methyl)-1,2,5-oxadiazole 2-oxide, with a MIC = 0.36 mu M, was not cytotoxic when tested on Vero cells (IC50 > 100 mu M). To complement the in vitro screening, we also studied the interaction of the test compounds with beta-ketoacyl acyl carrier protein synthase (FabH), the target for the parent compounds, and we observed three important hydrogen-bonding interactions with two important active site residues in the catalytic site of the enzyme, providing complementary evidence to support the target of the new hybrid molecules. (C) 2016 Elsevier Ltd. All rights reserved.
KW - Docking approach
KW - E. coli FabH potential inhibitors
KW - Furoxan hybrid derivatives
KW - Sulfonylhydrazone derivatives
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000380574400029&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.bmcl.2016.06.089
DO - 10.1016/j.bmcl.2016.06.089
M3 - Article
C2 - 27426865
SN - 0960-894X
VL - 26
SP - 3988
EP - 3993
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 16
ER -